Syndax reports 2Q26 revenue growth, details EGFR and menin inhibitor pipeline additions
Revuforj and Niktimvo both posted double-digit year-over-year net revenue growth as Syndax laid out new trial timelines for its expanded pipeline.
Syndax Pharmaceuticals reported financial results for the quarter ended June 30, 2026 and gave a business update on August 4, 2026. Revuforj net revenue reached $54.7 million in the second quarter of 2026, a 91% increase over the second quarter of 2025 and a 12% increase over the first quarter of 2026.1 Niktimvo net revenue reached $60.3 million in the second quarter, a 67% increase over the second quarter of 2025 and a 9% increase over the first quarter of 2026.1
In July 2026, Syndax added two pipeline candidates. SNDX-4321 is a mutant-selective, CNS-penetrant, allosteric EGFR inhibitor for non-small cell lung cancer that binds at a pocket adjacent to the ATP site, in contrast to third and fourth generation ATP-site directed EGFR inhibitors.1 The company expects to submit an IND for SNDX-4321 by the end of 2026 and start a Phase 1 trial in EGFRm NSCLC in 2027.1 SNDX-62122 is a next-generation menin inhibitor selected for development in myelofibrosis, the first candidate from an internally developed, wholly owned library of menin inhibitors.1 Syndax plans to submit an IND and start a Phase 1 trial of SNDX-62122 in myelofibrosis in 2027, informed by a separate Phase 1/2 proof-of-principle trial of revumenib in myelofibrosis expected to start in the fourth quarter of 2026 with initial data in the second half of 2027.1
On existing programs, the RAVEN Phase 2 trial combining revumenib with venetoclax and azacitidine in newly diagnosed KMT2Ar patients eligible for intensive chemotherapy is expected to start in the second half of 2026,1 and the MenTain Phase 2 trial, the first randomized, placebo-controlled study of revumenib as post-transplant maintenance, is expected to start around the end of 2026.1 For Niktimvo, topline data from a Phase 2 trial combining axatilimab with ruxolitinib in newly diagnosed chronic GVHD are anticipated in the fourth quarter of 2026,1 while a pivotal Phase 3 trial combining axatilimab with corticosteroids in newly diagnosed chronic GVHD is expected to report topline data in early 2028.1 Topline data from the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis are expected in the fourth quarter of 2026.1
On finances, Syndax held $575.1 million in cash, cash equivalents, and short- and long-term investments as of June 30, 2026, with 89.4 million common shares and prefunded warrants outstanding.1 For full year 2026, the company continues to expect combined research and development plus selling, general and administrative expenses of about $400 million, not counting an estimated $50 million in non-cash stock compensation expense.1 Syndax said its cash position, combined with anticipated product revenue, collaboration revenue and interest income, will enable the company to reach profitability.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.